Blake Borgeson - 05 Sep 2023 Form 4 Insider Report for RECURSION PHARMACEUTICALS, INC. (RXRX)

Role
Director
Signature
/s/ Jonathan Golightly, attorney-in-fact
Issuer symbol
RXRX
Transactions as of
05 Sep 2023
Net transactions value
-$78,136
Form type
4
Filing time
07 Sep 2023, 19:02:26 UTC
Previous filing
24 Aug 2023
Next filing
21 Sep 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RXRX Class A Common Stock Sale $78,136 -8,885 -0.12% $8.79 7,451,845 05 Sep 2023 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Sales are pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 9, 2022.
F2 The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $8.61 to $9.15 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request.